We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+41.14%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.71B
AUM Growth
-$3.29B
Cap. Flow
-$4.02B
Cap. Flow %
-85.46%
Top 10 Hldgs %
76.49%
Holding
126
New
17
Increased
33
Reduced
15
Closed
22

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$44.9M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$20.1M
3
BPMC
Blueprint Medicines
BPMC
+$19.9M
4
NKTR icon
Nektar Therapeutics
NKTR
+$15.4M
5
AUTL
Autolus Therapeutics
AUTL
+$13.9M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$3.48B
2
WW
WW International
WW
+$678M
3
INCY icon
Incyte
INCY
+$25M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$13.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 44.73%
2 Healthcare 36.61%
3 Miscellaneous 18.66%
4 Communication Services 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
76
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.85M 0.08%
110,000
– –
WVE icon
77
Wave Life Sciences
WVE
$879M
$3.83M 0.08%
100,000
-50,000
-33% -$2.15M
DVAX
78
CALL
DELISTED
Dynavax Technologies
DVAX
$3.81M 0.08%
250,000
– –
RCUS icon
79
Arcus Biosciences
RCUS
$3.1B
$3.67M 0.08%
300,000
– –
ACGN
80
DELISTED
Aceragen Inc
ACGN
$3.63M 0.08%
2,530
– –
TECX
81
Tectonic Therapeutic
TECX
$557M
$3.57M 0.08%
+10,417
New +$3.76M
MRNS
82
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.54M 0.08%
125,000
– –
VRDN icon
83
Viridian Therapeutics
VRDN
$2.47B
$3.21M 0.07%
33,333
– –
UBX
84
DELISTED
Unity Biotechnology
UBX
$3.01M 0.06%
+20,000
New +$2.92M
TCDA
85
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.99M 0.06%
+100,000
New +$2.79M
CRSP icon
86
CRISPR Therapeutics
CRSP
$5.01B
$2.94M 0.06%
50,000
+25,000
+100% +$1.42M
SGMO
87
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.84M 0.06%
200,000
+50,000
+33% +$831K
DNTH icon
88
Dianthus Therapeutics
DNTH
$5.86B
$2.7M 0.06%
+12,500
New +$2.82M
CMTA
89
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$2.63M 0.06%
200,000
– –
NTLA icon
90
Intellia Therapeutics
NTLA
$1.59B
$2.46M 0.05%
90,000
– –
CMRX
91
DELISTED
Chimerix, Inc.
CMRX
$2.38M 0.05%
500,000
– –
KRYS icon
92
Krystal Biotech
KRYS
$9.97B
$2.23M 0.05%
150,000
– –
ADVM
93
DELISTED
Adverum Biotechnologies
ADVM
$2.12M 0.05%
40,000
– –
QTTB icon
94
Q32 Bio
QTTB
$333M
$2.04M 0.04%
5,556
– –
KNSA icon
95
Kiniksa Pharmaceuticals
KNSA
$5.86B
$1.74M 0.04%
+100,000
New +$1.81M
SNNA
96
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$1.5M 0.03%
+99,000
New +$1.68M
XENE icon
97
Xenon Pharmaceuticals
XENE
$5.45B
$1.38M 0.03%
150,000
– –
NVLN
98
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$944K 0.02%
256,400
– –
FBRX
99
DELISTED
Forte Biosciences
FBRX
$934K 0.02%
267
– –
TRIL
100
DELISTED
Trillium Therapeutics Inc.
TRIL
$900K 0.02%
150,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2018 Portfolio in Review

As of Q2 2018, Artal Group held 126 positions worth $4.71B, down 41% from $7.99B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group withdrew a net $4.02B in Q2 2018, closing 22 positions and reducing 15 holdings. Its most notable exit was Blue Buffalo Pet Products, Inc, an estimated $3.48B position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 23% a quarter earlier, followed by Healthcare and Miscellaneous.

Against the trend, Artal Group opened a new position in Scholar Rock worth $37.4M.

  • Artal Group's largest Q2 2018 buy was Scholar Rock: 2,396,040 shares worth $37.4M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2018, an estimated $20.1M increase.
  • Artal Group's biggest Q2 2018 reduction was WW International, cutting an estimated $678M.
  • Artal Group fully exited Blue Buffalo Pet Products, Inc in Q2 2018, selling an estimated $3.48B.
  • Artal Group's ten largest holdings make up 76% of its $4.71B portfolio in Q2 2018.
  • Artal Group opened 17 new positions and closed 22 in Q2 2018.
  • Artal Group's portfolio value fell 41% quarter-over-quarter to $4.71B.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.